AI Finds Cancers Doctors Missed. Benchmarks Did Not Predict This. Clinical Reality Did.
AI in medicine has graduated from academic benchmarks to catching cancers missed in routine care, improving specialist diagnoses, and removing large portions of screening workloads. The same systems are now guiding surgeons live during procedures. Antibiotic discovery remains harder. Preclinical candidates still face toxicity and dosing challenges, and most experimental drugs never reach patients.
The principle here is domain-grounded evaluation. A model that wins benchmarks but misses tumors in clinical practice is useless. A model that catches what specialists miss is transformative. The mechanism is simple. Test against reality, not leaderboards. Stop worshipping benchmark scores. Demand clinical outcomes.
The medical AI community is deploying these systems in routine screening and live surgical contexts. Drug discovery remains stuck in preclinical stages due to toxicity and efficacy barriers.
- Open ChatGPT or Claude and paste a publicly available medical case study from any teaching hospital website. Ask the model to identify potential diagnoses.
- Compare its suggestions against the published diagnosis. Note what it catches and what it misses.
- Now ask it to explain its reasoning step by step. This reveals the diagnostic logic. You will see both strengths and gaps. This is clinical evaluation in miniature.